Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Halozyme Therapeutic
(NQ:
HALO
)
56.97
UNCHANGED
Streaming Delayed Price
Updated: 4:15 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Halozyme Therapeutic
< Previous
1
2
3
4
5
6
7
8
Next >
NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals.
July 12, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is probably undervalued for the fundamentals it is displaying.
Via
Chartmill
NASDAQ:HALO Shows Potential for a Breakout.
July 09, 2024
Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective.
Via
Chartmill
3 Highly Rated Biotech Stocks for Your July Buy List
July 05, 2024
Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street.
Via
InvestorPlace
3 Breakout Biotech Stocks on Track to Double by 2032
July 01, 2024
The tech sector has been at the forefront of the market rally in 2024. Consider these breakout biotech stocks as a great way to diversify.
Via
InvestorPlace
UroGen Pharma Stock Earns 91 RS Rating
June 27, 2024
UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier.
Via
Investor's Business Daily
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
June 26, 2024
Investors seeking growth at a reasonable cost should explore HALOZYME THERAPEUTICS INC (NASDAQ:HALO).
Via
Chartmill
Decoding 12 Analyst Evaluations For Halozyme Therapeutics
June 24, 2024
Via
Benzinga
NASDAQ:HALO: a strong growth stock preparing for the next leg up?.
June 24, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout.
Via
Chartmill
NASDAQ:HALO, a growth stock which is not overvalued.
June 04, 2024
NASDAQ:HALO stands out as a growth opportunity that won't break the bank.
Via
Chartmill
Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval
June 24, 2024
Sarepta Therapeutics had its Relative Strength (RS) Rating upgraded to 95 Monday, up from 68 a day earlier.
Via
Investor's Business Daily
Arcellx Stock Earns Relative Strength Rating Upgrade
June 21, 2024
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83.
Via
Investor's Business Daily
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
June 20, 2024
Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level.
Via
Investor's Business Daily
Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag.
June 19, 2024
In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals.
Via
Chartmill
The 3 Best Healthcare Stocks to Buy in June 2024
June 15, 2024
Aging populations and changing lifestyles mean healthcare is a secular story that these best healthcare stocks to buy will capitalize on.
Via
InvestorPlace
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
June 14, 2024
Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas.
Via
Investor's Business Daily
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.
May 14, 2024
Investors seeking growth at a reasonable cost should explore NASDAQ:HALO.
Via
Chartmill
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
June 12, 2024
On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90.
Via
Investor's Business Daily
Krystal Biotech Stock Sees RS Rating Jump To 91
June 11, 2024
On Tuesday, Krystal Biotech stock cleared a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88.
Via
Investor's Business Daily
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
June 09, 2024
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts.
Via
Benzinga
Halozyme Therapeutics Scores RS Rating Jump To 91
June 07, 2024
On Friday, Halozyme Therapeutics stock earned an upgrade to its Relative Strength (RS) Rating, from 80 to 91.
Via
Investor's Business Daily
This Exxon Mobil Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
June 07, 2024
Via
Benzinga
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 06, 2024
Via
Benzinga
Halozyme Therapeutics +13% On Thursday: What's Going On?
June 06, 2024
Halozyme Therapeutics surges as it raises FY24 guidance, driven by increased revenue projections and a new European patent for its drug delivery platform.
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
J.M. SmuckerPosts Upbeat Earnings, Joins Toro Company, United Natural Foods, Semtech And Other Big Stocks Moving Higher On Thursday
June 06, 2024
Via
Benzinga
A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 8 Analysts
June 04, 2024
Via
Benzinga
NASDAQ:HALO is probably undervalued for the fundamentals it is displaying.
May 29, 2024
In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals.
Via
Chartmill
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating
May 16, 2024
On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier.
Via
Investor's Business Daily
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
May 14, 2024
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79.
Via
Investor's Business Daily
The 3 Best Biotech Stocks to Buy in May 2024
May 09, 2024
If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May.
Via
InvestorPlace
When you look at NASDAQ:HALO, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
May 08, 2024
When you look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.